13. Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3

  1. Geoffrey W. McCaughan MBBS, PhD, FRACP3,4,
  2. John G. McHutchison MD5 and
  3. Jean-Michel Pawlotsky MD, PhD6,7
  1. Alessandra Mangia MD1,
  2. Leonardo Mottola PhD1 and
  3. Angelo Andriulli MD2

Published Online: 3 NOV 2011

DOI: 10.1002/9781444346343.ch13

Advanced Therapy for Hepatitis C

Advanced Therapy for Hepatitis C

How to Cite

Mangia, A., Mottola, L. and Andriulli, A. (2011) Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3, in Advanced Therapy for Hepatitis C (eds G. W. McCaughan, J. G. McHutchison and J.-M. Pawlotsky), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444346343.ch13

Editor Information

  1. 3

    Centenary Research Institute, Sydney, NSW, Australia

  2. 4

    Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia

  3. 5

    Liver Disease Therapeutics, Gilead Sciences, Inc., Foster City, CA, USA

  4. 6

    French National Reference Center for Viral Hepatitis B, C and delta, Créteil, France

  5. 7

    Department of Virology, Bacteriology, and Hygiene, INSERM U955, Hôpital Henri Mondor, Université Paris Est, Créteil, France

Author Information

  1. 1

    Liver Unit, IRRCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

  2. 2

    Gastroenterology Department, IRRCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

Publication History

  1. Published Online: 3 NOV 2011
  2. Published Print: 24 NOV 2011

ISBN Information

Print ISBN: 9781405187459

Online ISBN: 9781444346343

SEARCH

Keywords:

  • altered dosage, HCV genotypes 2/3;
  • genotype 2 or 3 HCV infection;
  • antiviral therapy;
  • sustained virologic response (SVR);
  • standard treatment duration;
  • HCV clearance;
  • Peginterferon Alfa dosages;
  • ribavirin dosages

Summary

The drugs currently licensed for treatment of hepatitis C are pegylated interferon and ribavirin. Variation of treatment length and dose modification of these drugs are the strategies that have been so far investigated to optimize the outcomes of treatment in patients with genotypes 2 and 3. The different design of the studies on shortening treatment duration and the rates of SVR, according to RVR, are reported and discussed in this chapter. Moreover, additional factors besides RVR that may improve patients' outcomes, reducing the rate of relapse after a short course of treatment, are analyzed. Finally, we focus on how drug dosing can influence treatment outcomes, increasing the efficacy of treatment.